Weir B
Can J Neurol Sci. 1984 May;11(2):239-46. doi: 10.1017/s0317167100045479.
The past fifteen years has seen the classification of diverse substances into a group known as calcium antagonists (CAs). They have a common ability to reduce the transmembrane transport of extracellular calcium ions (CAe2+). This flow of calcium into vascular smooth muscle is ultimately associated with the development of tension and vasoconstriction. Some CAs appear to have a predilection for cerebral as opposed to systemic arteries and so may function as specific cerebral arterial vasodilators. It has been proposed that they might be useful in certain types of cerebral ischemia such as that due to arterial occlusion or prolonged vasoconstriction. Animal experiments and initial clinical trials give grounds for cautious optimism that CAs may become as useful in neurology as they have recently become in cardiology.
在过去的十五年里，多种物质被归类为钙拮抗剂（CAs）。它们具有共同的能力，即减少细胞外钙离子（Ca²⁺）的跨膜转运。这种钙流入血管平滑肌最终与张力和血管收缩的发展相关。一些钙拮抗剂似乎对脑动脉而非全身动脉有偏好，因此可能作为特定的脑动脉血管扩张剂发挥作用。有人提出，它们可能对某些类型的脑缺血有用，比如由于动脉闭塞或长期血管收缩引起的脑缺血。动物实验和初步临床试验让人有理由谨慎乐观地认为，钙拮抗剂在神经病学领域可能会像它们最近在心脏病学领域一样有用。
